Login to Your Account



Replidyne Raises $40M, Adds To Pipeline With Antibacterial Drug

By Karen Pihl-Carey


Wednesday, August 18, 2004
Replidyne Inc. closed its largest financing, a $40 million second round, and concurrently in-licensed a late-stage compound to treat bacterial infections. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription